Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyEthyl carbamate
Identification
- Name
- Ethyl carbamate
- Accession Number
- DB04827
- Type
- Small Molecule
- Groups
- Withdrawn
- Description
Ethyl carbamate (also known as urethan and urethane), formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
- Structure
Structure for DB04827 (Ethyl carbamate)
- Synonyms
- Aethylcarbamat
- Aethylurethan
- Carbamic acid ethyl ester
- Carbamidsaeure-aethylester
- Estane 5703
- Ethyl ester of carbamic acid
- Ethyl urethan
- Ethyl urethane
- Ethylcarbamate
- Ethylester kyseliny karbaminove
- Ethylurethan
- Ethylurethane
- O-ethyl urethane
- O-ethylurethane
- Uretan
- Uretan etylowy
- Uretano
- Urethan
- Urethane
- Urethanum
- External IDs
- NSC-746
- International/Other Brands
- Leucethane / Leucothane / Pracarbamin / Pracarbamine
- Categories
- UNII
- 3IN71E75Z5
- CAS number
- 51-79-6
- Weight
- Average: 89.0932
Monoisotopic: 89.047678473 - Chemical Formula
- C3H7NO2
- InChI Key
- JOYRKODLDBILNP-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5)
- IUPAC Name
- ethyl carbamate
- SMILES
- CCOC(N)=O
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ethyl carbamate. Experimental Acepromazine The risk or severity of adverse effects can be increased when Acepromazine is combined with Ethyl carbamate. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Aceprometazine is combined with Ethyl carbamate. Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Ethyl carbamate. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Adipiplon The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl carbamate. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ethyl carbamate. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethyl carbamate. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl carbamate. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Ethyl carbamate. Approved Amperozide The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amperozide. Experimental Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ethyl carbamate. Approved, Investigational, Withdrawn Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl carbamate. Approved Azaperone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Azaperone. Investigational, Vet Approved Azelastine Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Ethyl carbamate. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate. Illicit Benperidol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl carbamate. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benzyl alcohol. Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Ethyl carbamate. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ethyl carbamate. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl carbamate. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Ethyl carbamate. Approved Brotizolam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl carbamate. Approved, Investigational Buprenorphine Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl carbamate. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Ethyl carbamate. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Ethyl carbamate. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate. Approved, Illicit, Vet Approved Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate. Approved Canertinib The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ethyl carbamate. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Ethyl carbamate. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethyl carbamate. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Ethyl carbamate. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ethyl carbamate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl carbamate. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethyl carbamate. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ethyl carbamate. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethyl carbamate. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Ethyl carbamate. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Ethyl carbamate. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Ethyl carbamate. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Ethyl carbamate. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Ethyl carbamate. Approved Clopenthixol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl carbamate. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl carbamate. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl carbamate. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Ethyl carbamate. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate. Approved Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Ethyl carbamate. Approved, Investigational Cyclopropane The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyclopropane. Experimental Cymarin Cymarin may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethyl carbamate. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Ethyl carbamate. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl carbamate. Approved Dapoxetine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Ethyl carbamate. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Ethyl carbamate. Approved Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Ethyl carbamate. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl carbamate. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl carbamate. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl carbamate. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Ethyl carbamate. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl carbamate. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Ethyl carbamate. Approved, Illicit Digitoxin Digitoxin may decrease the cardiotoxic activities of Ethyl carbamate. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Ethyl carbamate. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ethyl carbamate. Approved Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl carbamate. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl carbamate. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ethyl carbamate. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ethyl carbamate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl carbamate. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl carbamate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dixyrazine. Experimental Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate. Approved, Investigational Doramectin The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Ethyl carbamate. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Ethyl carbamate. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Ethyl carbamate. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Ethyl carbamate. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Ethyl carbamate. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl carbamate. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate. Approved, Investigational Ethanol Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl carbamate. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ethyl carbamate. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Ethyl carbamate. Approved Ethyl chloride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl carbamate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl carbamate. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate. Approved Etoperidone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl carbamate. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Ethyl carbamate. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Ethyl carbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl carbamate. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl carbamate. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Ethyl carbamate. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Ethyl carbamate. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ethyl carbamate. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Ethyl carbamate. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl carbamate. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl carbamate. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethyl carbamate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl carbamate. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ethyl carbamate. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl carbamate. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Ethyl carbamate. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethyl carbamate. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Gepirone. Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Ethyl carbamate. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Ethyl carbamate. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Ethyl carbamate. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Ethyl carbamate. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate. Approved Hydrocodone Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl carbamate. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Ethyl carbamate. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Ethyl carbamate. Approved Indalpine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indiplon. Investigational Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Ethyl carbamate. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate. Approved Ketobemidone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ethyl carbamate. Approved, Investigational Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethyl carbamate. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethyl carbamate. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethyl carbamate. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Ethyl carbamate. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl carbamate. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Lithium is combined with Ethyl carbamate. Approved Lofentanil The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Ethyl carbamate can be increased when used in combination with Lofexidine. Approved, Investigational Loprazolam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Ethyl carbamate. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl carbamate. Approved Lormetazepam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl carbamate. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Ethyl carbamate can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Ethyl carbamate. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Ethyl carbamate. Approved Medazepam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Ethyl carbamate. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl carbamate. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Ethyl carbamate. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethyl carbamate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethyl carbamate. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate. Approved Methotrimeprazine Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl carbamate. Approved Methylecgonine The risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethyl carbamate. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl carbamate. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Metyrosine Ethyl carbamate may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved, Investigational Mirtazapine Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Molindone is combined with Ethyl carbamate. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl carbamate. Approved Nefazodone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethyl carbamate. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethyl carbamate. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl carbamate. Approved, Investigational Oleandrin Oleandrin may decrease the cardiotoxic activities of Ethyl carbamate. Experimental, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Ethyl carbamate. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl carbamate. Approved Opium The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Opium. Approved, Illicit Orphenadrine Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant. Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Ethyl carbamate. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate. Approved Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl carbamate. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate. Approved, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl carbamate. Approved Paraldehyde Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved Perazine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl carbamate. Approved Phenazocine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Phenoxyethanol. Approved Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Ethyl carbamate. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate. Approved Pipamperone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Ethyl carbamate. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Ethyl carbamate. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethyl carbamate. Approved Pramipexole Ethyl carbamate may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate. Approved, Illicit Pregabalin The therapeutic efficacy of Ethyl carbamate can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Ethyl carbamate. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Ethyl carbamate. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Ethyl carbamate. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl carbamate. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Ethyl carbamate. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Propoxycaine. Approved Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Ethyl carbamate. Experimental Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl carbamate. Approved Proxibarbal The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate. Approved Quinisocaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl carbamate. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl carbamate. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Romifidine. Vet Approved Ropinirole Ethyl carbamate may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate. Approved Rotigotine Ethyl carbamate may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl carbamate. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethyl carbamate. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Ethyl carbamate. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl carbamate. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sultopride. Experimental Suvorexant Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Ethyl carbamate. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ethyl carbamate. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrodotoxin. Investigational Thalidomide Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl carbamate. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl carbamate. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl carbamate. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Ethyl carbamate. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Ethyl carbamate. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Ethyl carbamate. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Ethyl carbamate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Ethyl carbamate. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl carbamate. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl carbamate. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Ethyl carbamate. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Ethyl carbamate. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethyl carbamate. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Ethyl carbamate. Approved Vinyl ether The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Ethyl carbamate. Approved Zimelidine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate. Approved Zolazepam The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zolazepam. Vet Approved Zolpidem Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Ethyl carbamate. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Ethyl carbamate. Approved Zotepine The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Norton A. Cashen, "Method of producing anhydrous crystalline reaction products of formaldehyde and methyl-, ethyl carbamate." U.S. Patent US4002668, issued July, 1973.
US4002668- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0031219
- KEGG Compound
- C01537
- PubChem Compound
- 5641
- PubChem Substance
- 46505215
- ChemSpider
- 5439
- ChEBI
- 17967
- ChEMBL
- CHEMBL462547
- Wikipedia
- Urethane
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 49 °C PhysProp boiling point (°C) 185 °C PhysProp water solubility 4.8E+005 mg/L (at 15 °C) SEIDELL,A (1941) logP -0.15 HANSCH,C ET AL. (1995) logS 0.85 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 371.0 mg/mL ALOGPS logP -0.14 ALOGPS logP -0.054 ChemAxon logS 0.62 ALOGPS pKa (Strongest Acidic) 15.47 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 52.32 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 20.84 m3·mol-1 ChemAxon Polarizability 8.64 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9922 Caco-2 permeable + 0.516 P-glycoprotein substrate Non-substrate 0.892 P-glycoprotein inhibitor I Non-inhibitor 0.9593 P-glycoprotein inhibitor II Non-inhibitor 0.9677 Renal organic cation transporter Non-inhibitor 0.9397 CYP450 2C9 substrate Non-substrate 0.8579 CYP450 2D6 substrate Non-substrate 0.7888 CYP450 3A4 substrate Non-substrate 0.7321 CYP450 1A2 substrate Non-inhibitor 0.5553 CYP450 2C9 inhibitor Non-inhibitor 0.9306 CYP450 2D6 inhibitor Non-inhibitor 0.9168 CYP450 2C19 inhibitor Non-inhibitor 0.9537 CYP450 3A4 inhibitor Non-inhibitor 0.9765 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9452 Ames test AMES toxic 0.7773 Carcinogenicity Non-carcinogens 0.6285 Biodegradation Ready biodegradable 0.6313 Rat acute toxicity 1.6607 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9864 hERG inhibition (predictor II) Non-inhibitor 0.9783
Spectra
- Mass Spec (NIST)
- Download (8.45 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-01r7-9000000000-ba57e1f4b939a6bb2c1c GC-MS Spectrum - EI-B GC-MS splash10-01r7-9000000000-4905daa85aa870eff5d7 Mass Spectrum (Electron Ionization) MS splash10-01r7-9000000000-dbaaf921e6f73cb42292 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available 1H NMR Spectrum 1D NMR Not Applicable 13C NMR Spectrum 1D NMR Not Applicable
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as carboximidic acids and derivatives. These are compounds containing a carboximidic group, with the general formula R-C(=NR1)OR2.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboximidic acids and derivatives
- Sub Class
- Not Available
- Direct Parent
- Carboximidic acids and derivatives
- Alternative Parents
- Organopnictogen compounds / Organooxygen compounds / Imines / Hydrocarbon derivatives
- Substituents
- Carboximidic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Imine / Aliphatic acyclic compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- carbamate ester (CHEBI:17967) / a small molecule (URETHAN)
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Phospholipase a2 activity
- Specific Function
- Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
- Gene Name
- PLA2G4A
- Uniprot ID
- P47712
- Uniprot Name
- Cytosolic phospholipase A2
- Molecular Weight
- 85238.2 Da
References
- Dinnes DL, Santerre JP, Labow RS: Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9. [PubMed:15626436]
- Labow RS, Santerre JP, Waghray G: The effect of phospholipids on the biodegradation of polyurethanes by lysosomal enzymes. J Biomater Sci Polym Ed. 1997;8(10):779-95. [PubMed:9297603]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Peroxidase activity
- Specific Function
- Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
- Gene Name
- MPO
- Uniprot ID
- P05164
- Uniprot Name
- Myeloperoxidase
- Molecular Weight
- 83867.71 Da
References
- Kotanidou A, Choi AM, Winchurch RA, Otterbein L, Fessler HE: Urethan anesthesia protects rats against lethal endotoxemia and reduces TNF-alpha release. J Appl Physiol (1985). 1996 Nov;81(5):2305-11. [PubMed:8941558]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xanthine dehydrogenase activity
- Specific Function
- Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
- Gene Name
- AOX1
- Uniprot ID
- Q06278
- Uniprot Name
- Aldehyde oxidase
- Molecular Weight
- 147916.735 Da
References
- Sugihara K, Kitamura S, Tatsumi K: Involvement of liver aldehyde oxidase in conversion of N-hydroxyurethane to urethane. J Pharmacobiodyn. 1983 Sep;6(9):677-83. [PubMed:6689178]
Drug created on September 11, 2007 14:32 / Updated on June 02, 2018 07:35